Abstract: Compounds of the formula ##STR1## wherein R is --COCH.sub.3, --CHOHCH.sub.3, --COCH.sub.2 OH, or --CHOHCH.sub.2 OH; hydrogen; hydroxyl; a 1 to 3 carbon alkyl; a 1 to 3 carbon .omega.-hydroxyalkyl; a 2 to 7 carbon organic acid ester or diester of --COCH.sub.2 OH, --CHOHCH.sub.2 OH, or --CHOHCH.sub.3 ; or the groups --COCH.sub.2 OH, --CHOHCH.sub.2 OH, or --CHOHCH.sub.3 having a 1 to 6 carbon alkyl or aryl ether replacement of one or more hydroxyls; or 13-ketimine derivatives of --COCH.sub.3 or --COCH.sub.2 OH;Y is methoxy, hydroxy, or hydrogen; and X is O or NH, but when Y is hydroxy or hydrogen, X must be O;and wherein R' is a 1 to 3 carbon alkyl; andor wherein Z is O, S, CH.sub.2 or CHOR' wherein R' is 1 to 3 carbon alkyl,and the pharmaceutically acceptable acid additive salts thereof; are useful for retarding tumor proliferation.

Abstract: Compounds of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein R is: --CO--CH.sub.3, --CHOH--CH.sub.3, --CO--CH.sub.2 OH, --CHOH--CH.sub.2 OH, hydrogen, hydroxy, 1 to 3 carbon alkyl, 1 to 3 carbon terminal hydroxyalkyl; or,a 2 to 7 carbon ester or diester of said --CO--CH.sub.2 OH, --CHOH--CH.sub.2 OH, --CHOH--CH.sub.3 or of said 1 to 3 carbon terminal hydroxyalkyl; orsaid --CO--CH.sub.2 OH, --CHOH--CH.sub.2 OH, or --CHOH--CH.sub.3 or said 1 to 3 C-terminal hydroxyalkyl having 1 to 6 carbon alkyl or aryl ether replacements of one or more of the hydroxyls; orthe 13-ketimine derivatives of --CO--CH.sub.3 and --CO--CH.sub.2 OH;Y is hydrogen, hydroxy, or methoxy,X is O or NH, but when Y is hydrogen or hydroxy, X must be O;at least one of R.sup.1 and R.sup.

Abstract: A group of new daunorubicin and doxorubicin derivatives is disclosed. Included in this group are 3'-deamino-3'(3"-cyano-4"-morpholinyl doxorubicin; 3'-deamino-3'-(3"-cyano-4"-morpholinyl)-13-dihydoxorubicin; (3'-deamino-3'-(3"-cyano-4"-morpholinyl) daunorubicin; 3'-deamino-3'-(3"-cyano-4"-morpholinyl)-3-dihydrodaunorubicin; and 3'-deamino-3'-(4"-morpholinyl-5-iminodoxorubicin and derivatives thereof which have excellent activity as antitumor agents.

Abstract: A group of new daunorubicin and doxorubicin derivatives is disclosed. These materials have the formula ##STR1## wherein R is CO--CH.sub.3 or CHOH--CH.sub.3 in the case of daunorubicin derivatives or CO--CH.sub.2 OH or CHOH--CH.sub.2 OH in the case of doxorubicin derivatives; X is O or NH; and A is either a cyano group (CN) or a hydrogen, subject to the limitation that when X is O, A must be a cyano group. When A is hydrogen, these compounds can exist as acid addition salts, as well. Derivatives of these compounds are disclosed as well.

Abstract: 5-Iminodoxorubicin and its pharmaceutically acceptable acid addition salts having good antitumor activity.

Abstract: Adriamycin octanoylhydrazone, and its pharmaceutically acceptable salts, having good antitumor activity coupled with low toxicity.

Abstract: Described are N,N-pentamethylene derivatives of daunomycin and adriamycin having the formula: ##STR1## wherein R.sup.1 is --COCH.sub.3 or --CHOHCH.sub.3 in the case of daunomycin derivatives, or --COCH.sub.2 OH or --CHOHCH.sub.2 OH in the case of adriamycin derivatives. The compounds have utility as antitumor agents.

Abstract: Rubidazone analogs wherein the phenyl group is substituted by one of 4-phenyl, 4-chloro, 3,4-dichloro or 3-nitro, said compounds having high antitumor activity coupled with desirably low cardiotoxicity.

Abstract: Bis-hydrazones of daunomycin and adriamycin having useful antitumor characteristics and the structure ##STR1## WHEREIN N IS AN INTEGER HAVING A VALUE OF FROM 0 THROUGH 8 AND THE RADICALS INDICATED BY R and R' each represent hydrogen except that in those instances in which n has a value of 2, the R groups, if not hydrogen, may be methyl radicals (with R' remaining as hydrogen), and the R' groups, if not hydrogen, may be hydroxy radicals (with R remaining as hydrogen).

Abstract: 5-Iminodaunomycin having good antitumor activity coupled with low cardiotoxicity.